CGRP Inhibitor Market to Grow with a CAGR of 7.23% through 2028
Rising ongoing investments in research and development are
expected to drive the Global CGRP Inhibitor Market growth in the forecast
period, 2024-2028.
According to TechSci Research report, “CGRP
Inhibitor Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global CGRP Inhibitor Market stood
at USD 1.41 billion in 2022 and is anticipated to grow with a CAGR of 7.23% in
the forecast period, 2024-2028. The Global CGRP (Calcitonin Gene-Related
Peptide) Inhibitor Market has been experiencing remarkable growth in recent
years, driven by a confluence of factors that have reshaped the landscape of
migraine and headache treatment. A critical driver of the CGRP inhibitor market's
growth is the escalating prevalence of migraine and cluster headache disorders.
These conditions affect millions of individuals worldwide, significantly
impacting their quality of life and daily functioning. As awareness of these
disorders increases, more patients are seeking effective treatment options,
which has led to a surge in demand for CGRP inhibitors. Traditional treatments
for migraines, such as over-the-counter pain relievers and preventive
medications, often provide limited relief and can be associated with
undesirable side effects. This inadequacy of existing therapies has created a
substantial unmet medical need, prompting both patients and healthcare
providers to explore alternative treatments like CGRP inhibitors, which have
demonstrated superior efficacy and safety profiles. The U.S. Food and Drug
Administration (FDA) has played a pivotal role in fostering the growth of the
CGRP inhibitor market. The agency's approval of several CGRP inhibitors has not
only validated their safety and efficacy but has also paved the way for further
research and development in this field. These approvals have bolstered the
confidence of pharmaceutical companies in investing resources into CGRP
inhibitor development and have increased accessibility to these innovative
treatments for patients. Pharmaceutical companies have been making substantial
investments in research and development to bring novel CGRP inhibitors to the
market. This commitment to innovation has led to the discovery of various CGRP
inhibitor formulations, including monoclonal antibodies and small molecules,
each with its unique mechanisms of action. These investments have not only
expanded the product portfolio but have also improved the overall efficacy of
CGRP inhibitors.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global CGRP Inhibitor Market.”
Initially developed to target migraines, CGRP
inhibitors are now being explored for a broader range of therapeutic
indications. Clinical trials are underway to investigate their potential in
conditions like fibromyalgia, post-traumatic headache, and more. This
diversification of applications is expected to drive CGRP inhibitor adoption
and market growth. The Global CGRP Inhibitor Market is segmented into Treatment
, Route of Administration, End-User, Regional Distribution, And Company. Based
on the Hospitals the Hospitals emerged as the dominant segment in the global
market for Global CGRP Inhibitor Market in 2022. Hospitals often serve as
centers of specialized medical care, including the treatment of neurological
and pain-related conditions that CGRP inhibitors are designed to address. These
facilities have the expertise and resources to manage patients with complex
medical needs, making them a natural choice for CGRP inhibitor administration. Hospitals
offer both inpatient and outpatient services, allowing them to cater to a broad
spectrum of patients. While some patients may receive CGRP inhibitors in an
outpatient setting, others with more severe conditions may require
hospitalization, creating a diverse demand for these medications within
hospital environments.
Based on the Route of Administration, the Oral segment
emerged as the dominant player in the global market for Global CGRP Inhibitor
Market in 2022. Oral medications are generally more convenient for patients.
They can be taken easily with a glass of water, eliminating the need for
injections or specialized equipment. This convenience often leads to better
patient compliance and adherence to treatment regimens. Oral administration is
non-invasive, making it more comfortable and less intimidating for patients. It
avoids the pain and potential complications associated with intravenous
injections or nasal administration. Oral medications are typically more
cost-effective to produce and administer compared to intravenous treatments,
which often require healthcare professionals for administration. This
cost-effectiveness can make oral CGRP inhibitors a preferred choice for both
patients and healthcare systems. North America emerged as the dominant player
in the global CGRP Inhibitor Market in 2022, holding the largest market share.
North America boasts a robust healthcare infrastructure and advanced research
and development capabilities, making it a hub for pharmaceutical innovation.
The region's numerous pharmaceutical companies and research institutions have
played a pivotal role in pioneering CGRP inhibitor drugs, driving their
development and commercialization. The high prevalence of migraine and cluster headache
disorders in North America has contributed significantly to the market's
dominance. These conditions affect millions of individuals in the region,
creating a substantial patient pool in need of effective treatments like CGRP
inhibitors. Also, the
regulatory environment in North America, particularly in the United States, has
been favorable for CGRP inhibitor approvals. The FDA's timely approval of
several CGRP inhibitors has facilitated their rapid entry into the market,
further solidifying North America's position as a dominant player. Additionally, North America's strong focus on
patient-centered healthcare and comprehensive insurance coverage has ensured
that patients have access to these innovative treatments, despite their
relatively high costs.
Major companies operating in Global CGRP
Inhibitor Market are:
- Eli Lilly and
Company
- Pfizer Inc.
- Teva Pharmaceutical
Industries Ltd
- AbbVie Inc.
- Amgen Inc
- Novartis AG
- Allergan
- Biohaven
Pharmaceutical Holding Company Ltd.
- Sun Pharmaceutical
Industries Ltd.
- Alder
BioPharmaceuticals (Acquired by Lundbeck)
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global CGRP
(Calcitonin Gene-Related Peptide) Inhibitor Market is poised for substantial
growth in the coming years. This anticipation stems from several key factors,
including the rising prevalence of migraine and cluster headache disorders
worldwide, an ever-increasing focus on patient-centric healthcare, and ongoing
advancements in biotechnology and neuroscience. The market's growth is further
bolstered by increasing FDA approvals for CGRP inhibitors, expanding the range
of therapeutic indications beyond migraines, and the emergence of biosimilars
and generics, making these innovative treatments more affordable and
accessible. Moreover, the exploration of combination therapies and personalized
medicine approaches promises to enhance the efficacy of CGRP inhibitors,
improving treatment outcomes for a broader patient base.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management consulting
firm.
“CGRP Inhibitor Market - Global Industry Size,
Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product
(Adjuvant Emulsions, Pathogen Components, Saponin-Based Adjuvants, Particulate
Adjuvants, Other Adjuvants), By Type (Human Vaccine Adjuvants, Veterinary
Vaccine Adjuvants), By Application (Research Applications, Commercial
Applications) By Region and Competition”, has evaluated the future growth
potential of Global CGRP Inhibitor Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global CGRP Inhibitor Market.
Contact
Mr. Ken Mathews
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com